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Abstract. Gametocytes are the malaria parasite stages responsible for transmission from humans to mosquitoes.
Gametocytemia often follows drug treatment, especially as therapies start to fail. We examined Plasmodium falciparum
gametocyte carriage and drug resistance profiles among 824 persons with uncomplicated malaria in Cambodia to
determine whether prevalent drug resistance and antimalarial use has led to a concentration of drug-resistant parasites
amonggametocyte carriers. Although report of prior antimalarial use increased from2008 to2014, theprevalenceof study
participants presenting with microscopic gametocyte carriage declined. Gametocytemia was more common in those
reporting antimalarial use within the past year, and prior antimalarial use was correlated with higher IC50s to piperaquine
and mefloquine, as well as to increased pfmdr1 copy number. However, there was no association between microscopic
gametocyte carriage and parasite drug resistance. Thus, we found no evidence that the infectious reservoir, marked by
those carrying gametocytes, is enriched with drug-resistant parasites.
Cambodia, long an epicenter ofmultidrug-resistantmalaria,
has been the focus of malaria containment efforts since
artemisinin resistance was reported in 2008–2009.1 Efforts to
halt the spread of drug-resistant malaria with the use of
artemisinin-based combination therapies (ACTs) combined
with widespread private sector use of antimalarials has led to
substantial in vivo drug pressure in the region.2–4 Historically,
drug treatment has been linked to carriage of Plasmodium
falciparum gametocytes, the parasite stages responsible for
human-to-mosquito transmission, especially as resistance
emerges.5 Patientswith prolonged parasite clearance times in
the Tracking Resistance to Artemisinin Collaboration study
were more likely to carry gametocytes both pre- and post-
treatment.6 Recrudescent parasitemias are also associatedwith
gametocyte carriage.7,8 This raises the question of whether re-
peated treatment of drug-resistant parasites among a relatively
small pool of at-risk persons in western Cambodia is leading to
enhanced transmission of drug-resistant parasites.9
We sought to address this question by examining whether
gametocyte carriers in Cambodia were more likely to harbor
drug-resistant parasites. In pooled study data on 824 persons
aged13–65yearswith uncomplicated smear-positivemalaria,
we evaluated the relationship of gametocyte carriage to prior
antimalarial use and the association of both prior antimalarial
use and gametocyte carriagewith parasite drug resistance, as
defined by phenotypic and molecular assays. Subjects were
originally enrolled from north, west, and southern Cambodia
from 2008 to 2014 as part of four clinical protocols: WR1396
(N = 143) in 2008–2009, WR1737 (N = 21) in 2010–2011,
WR1877 (N = 119) in 2013–2014, and WR1576 (N = 541) in
2009–2014.2 All subjects provided informed consent before
participation, and all study protocols were approved by the
Cambodian National Ethics Committee for Health Research
and the Walter Reed Army Institute of Research Institutional
Review Board.
At enrollment, participants were asked about duration of
symptoms, history of malaria infection, and antimalarial use
within thepast year. Thosewith recent antimalarial use,within the
previous 7–30 days (varying for each protocol), were excluded
from participation. To facilitate recall of prior antimalarial use, the
participants were shown samples of antimalarials available in
Cambodia and local packagesof commonlyusedantibiotics and
cold medicines (Supplemental Figure 1). Pill sample packages
were updated every year. Twomicroscopists examinedGiemsa-
stainedbloodsmears todetermineP. falciparumgametocytemia,
basedon thenumberofgametocytesper200whitebloodcellsor
5,000 red blood cells. Molecular detection of gametocytes by
reverse transcriptase polymerase chain reaction (RT-PCR) of
Pfs25 was performed in two of the clinical studies (N = 256 from
WR1396 and WR1877).10,11 Parasite drug resistance profiles
were measured before treatment by ex vivo drug susceptibility
assays based on an histidine-rich protein-2 enzyme-linked im-
munosorbent assay.2,12 For this analysis,we focused specifically
on resistance to chloroquine (IC50 > 87 nM), mefloquine (MQ)
(IC50>24nM), andpiperaquine (PPQ) (IC50 in top25thpercentile),
as artesunate (AS) and MQ, and dihydroartemisinin (DHA) and
PPQ are the most commonly used ACTs in the region. Mea-
surement of piperaquine IC50s began in 2010. In addition, gen-
otyping of two molecular markers of resistance were included in
the analysis: P. falciparum multidrug resistance gene (Pfmdr1)
amplification associated with MQ resistance,13 and kelch13
mutation associated with artemisinin resistance.6,14
We have previously reported high rates of drug resistance
and prevalent antimalarial use in the region.2 IC50s to chlo-
roquine and MQ in the cohort reflect high-grade resis-
tance (median [interquartile range] 160 nm [94–237 nm] and
61 nm [33–106 nm], respectively), although rising IC50s to
PPQ in the latter years of the study (2013–2014) were ac-
companied by a reciprocal fall in MQ IC50s. Kelch mutations
have been present in the majority of tested isolates since
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2008 (431/493, 87%), predominantly C580Y (79%, N = 340)
and R539T (21%, N = 72). More than half of participants re-
ported antimalarial use within the previous 12 months (61%,
440/720),most commonly AS-MQ (34%,N= 148), DHA-PPQ
(22%,N = 95), or chloroquine (13%,N = 59, typically given for
Plasmodium vivax infection). Rates of prior antimalarial use
rose over time, with widespread use of artemisinin-based
therapies by 2012–2014 (Figure 1). In addition, a bioassay
used to measure antimalarial activity in plasma found that
roughly 18%of individuals in this cohort showed evidence of
recent antimalarial use.2
Despite a high prevalence of multidrug-resistant parasites
and increasing numbers of patients reporting multiple malaria
treatmentcoursesover12months, theproportionofgametocyte
carriers at enrollment appeared to decline over time (Figure 1).
Gametocyteprevalence in2008bymicroscopywas22%(13/58)
in 2008, falling to 11% (14/134) in 2012–2014. This apparent
decline ingametocyte carriagewasnot associatedwith changes
in the levels of parasitemia in patients seeking care (median
parasite density 10,388 p/μL in 2008 and 9,621–12,325 p/μL in
2012–2014) or earlier access to care (median days of illness re-
portedwas 3 days in all years of the study). It may be associated
with increasing use of artemisinin-based therapies (Figure 1)
and/or a decline in transmission intensity as a result of malaria
control efforts in the region.15
Among the 123 persons who were gametocyte positive by
microscopy, risk factors for gametocyte carriage were similar
to those seen in other surveys (Table 1).5,7 Gametocytemic
individuals were more likely to report prior malaria illness and
antimalarial usewithin the past year. They also presented later
in illness, had lower asexual parasite densities, and were less
likely to be febrile, but more likely to be anemic. These risk
factors are consistent with previous exposure to malaria and
acquired immunity. Most of these associations were lost
when expanding the definition of gametocyte carriage to in-
clude those with submicroscopic gametocytes detectable by
RT-PCR (Table 1).
As might be expected, antimalarial use within the past year
was associated with infection with drug-resistant parasites
(Figure 2A, Supplemental Table 1). In those reporting prior
antimalarial use, the mean number of illnesses believed or
confirmed to be due to malaria over the past year was 2.8
episodes. Although most of the parasite isolates displayed
chloroquine and mefloquine resistance, ex vivo PPQ re-
sistance was more prevalent in persons reporting prior anti-
malarial use (prevalence ratio of 1.3 [95% confidence interval
[CI] 0.9–2.0]), as was the increased pfmdr1 copy number
(prevalence ratio of 1.6 [95% CI 1.3–2.1]).
Although gametocytemia was more common in those
reporting antimalarial use within the previous 12 months and anti-
malarial use was correlated with infection with drug-resistant para-
sites, we did not find that gametocyte carriers were more likely to
harbor drug-resistant parasites (Figure 2B). In both crude and ad-
justed analyses, the prevalence of ex vivo drug resistance or mo-
lecular markers of drug resistance were not different in those with
and without microscopic gametocytes (Supplemental Table 1).
Accordingly, gametocytemia was not more common in those with
mefloquine- or PPQ-resistant malaria (Supplemental Figure 2). To
some extent, nearly all parasites in the region are drug resistant, in
that only 13% (40/303) of persons in the cohort were bothMQ and
PPQsensitiveand60%(24/40)of thesestillharboredaC580Ykelch
mutation. However, taken together, our findings do not support the
notion that increasing drug resistance and use of failing drugs are
leading to preferential transmission of drug-resistant parasites.
There are several limitations of this study. This was not a
population-based study, and the inclusion of consecutive
FIGURE 1. Gametocyte prevalence (A) and reported antimalarial use (B and C) in persons presenting with uncomplicated falciparum malaria in
Cambodia from 2008 to 2014. Gametocyte prevalence (gray bars) refers to the proportion of study participants with gametocytemia detected by
microscopy at enrollment. Antimalarial use denotes reported usage over the previous 12-month (recent antimalarial use in the preceding 7 days
(WR1576) or 28–30 days (WR1877 and WR1396 were exclusion criteria). Artemisinin-based combination therapies (ACTs) reported included
dihydroartemisinin–piperaquine or artesunate–mefloquine combinations, and non-ACT use was predominantly chloroquine for vivax malaria.
Artesunate and artemether were included with ACTs, whereas antimalarial use reported as unknown is denoted as missing data.
studies conducted in the same region may still draw from
heterogeneous populations. However, when we confined the
analysis to individual studies, no trends linking gametocyte
carriage and drug resistance were found. Mefloquine- and
PPQ-resistant parasites in the region display opposing re-
sistance profiles,16,17 which may render it difficult to detect
associations with drug resistance. Because of limited data,
results from the ring stage survival assay for artemisinin re-
sistance and testing for amplification of plasmepsin 2-3, a
recently described marker for PPQ resistance,18,19 were not
included. Finally, drug susceptibility assays are reliant on
growth of parasites in short-term culture and tend to fail when
antimalarials are present in plasma. Thismay lead to sampling
bias, with the most resistant parasites potentially excluded
from analysis because of missing IC50 data.
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Despite these limitations, our findings likely reflect that a
complex interplay of host and parasite factors affect game-
tocytogenesis. Although persons reporting prior antimalarial
use increased over time and these individuals were more
likely to harbor gametocytes and drug-resistant parasites,
the proportion of gametocyte carriers did not increase over
time, and gametocyte carriers did not harbor more drug-
resistant parasites compared with those without gameto-
cytes. It is likely that host immunity plays an equally important
role in determining who is gametocytemic and contributes to
the infectious reservoir.5 Although this study comprised a
symptomatic cohort, it would be useful to evaluate the
prevalence of drug-resistant parasites in asymptomatic ga-
metocyte carriers.
In conclusion, increasing and prevalent drug resistance in
Cambodia does not seem to have led to a rise in gametocyte
carriage among malaria patients, perhaps because of wide-
spreadACTuse20 and decliningmalaria transmission.We found
no evidence that the infectious reservoir, marked by those car-
rying gametocytes, is enriched with drug-resistant parasites.
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Potential risk factors
Smear positive for gametocytes Smear negative for gametocytes
P valueN = 123 N = 701
Age (years), median (IQR) 27 (20–37) 27 (21–37) 0.36
Female gender (%) 23 (19) 97 (14) 0.16
Days of illness, median (IQR) 3 (2–6) 3 (2–3) < 0.0001*
Fever (temperature ³ 38C) (%) 58 (47) 507 (72) < 0.0001*
Number of illnesses believed to be due to
malaria in the last 12months,median (IQR)
2 (1–4) 1 (0–4) < 0.0001*
At least one believed malaria infection in the
last 12 months (%)
81 (84) 318 (56) < 0.0001*
Antimalarial usage in last 28 days (%) 15 (13) 38 (6) 0.01
Antimalarial usage in last year (%) 95 (83) 345 (57) < 0.0001*
Hematocrit, median (IQR) 35 (30–38) 40 (38–44) < 0.0001*
Asexual parasite density (parasites/μL),
median (IQR)
6,214 (2,726–19,596) 13,057 (4,768–48,450) < 0.0001*
Mixed species infection (%) 8 (7) 45 (6) 0.97
Potential risk factors
Gametocytes detected by RT-PCR Gametocytes not detected by RT-PCR
P valueN = 79 N = 177
Age, median (IQR) 25 (21–33) 25 (20–35) 0.52
Female gender (%) 6 (8) 27 (15) 0.09
Days of illness, median (IQR) 3 (2–4) 3 (2–3) 0.08
Fever (temperature ³ 38C) (%) 43 (54) 106 (60) 0.41
Number of illnesses believed to be due to
malaria in the last 12months,median (IQR)
0 (0–1) 0 (0–1) 0.50
At least one believed malaria infection in the
last 12 months (%)
24 (49) 27 (40) 0.32
Antimalarial usage in last 28 days (%) 1 (2) 2 (2) 0.80
Antimalarial usage in last year (%) 37 (47) 54 (31) 0.18
Hematocrit, median (IQR) 40 (36–43) 41 (38–44) 0.01
Asexual parasite density, median (IQR) 19,548 (6,419–45,558) 14,499 (4,776–38,306) 0.40
Mixed infection (%) 5 (6) 7 (4) 0.41
IQR = interquartile range. Categorical variables are expressed as N (%) and continuous variables are expressed as median (IQR). Note that denominators may vary based on missing data and
RT-PCR data were only available for studies WR1396 and WR1877.
*P < 0.004 with P values calculated by two-tailed Wilcoxon rank sum tests.
TABLE 1
Risk factors for gametocyte carriage, as detected by microscopy (top) or Pfs25 RT-PCR (bottom)
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